“We don’t have a single pill in our portfolio”
Camilla Harder Hartvig has moved from senior positions with Novartis and AstraZeneca to becoming the head of Allergan’s Nordic business - and the task of having to interact with healthcare bodies on behalf of her new company presents brand new challenges.
BY STEFAN SINGH KAILAY
In the midst of widespread M&A buzz and intense interest from other major players in the market, US-based pharma group Allergan has brought in a new general manager for its Nordic business.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
